Trial Profile
A Retrospective Clinical Study on the Adjuvant Treatment of Glioblastoma After Simultaneous Radiotherapy With Anti-angiogenesis Drugs Combined With Temozolomide
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 29 Feb 2020 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 25 Apr 2019 Planned number of patients changed from 50 to 60.